Preparing for a New Treatment in Atopic Dermatitis

In just 1 week, we surveyed 42 Canadian Dermatologists on:

• their decision making factors for treatment,
• how they've interacted with manufacturers of treatments,
• and their awareness of a new treatment coming to market.

The average physician sees 10 atopic dermatitis patients every week, with about one third of patients being moderate to severe.

A bigger proportion of atopic dermatitis patients have private coverage compared to the overall patient population. Dupilumab is the most well-known drug for atopic dermatitis, most report having expert-level familiarity.

20% of survey respondents were from the west provinces, 50% from Ontario and 30% from Quebec.

We partnered with Dr. Jordana Schachter, a Quebec Dermatologist, who has provided a reflection of her thoughts on the results throughout the final report.

Contributing to our knowledge of diversity in Atopic Dermatitis patients, Dermatologists identified that Chinese patients are more likely to have severe atopic dermatitis, followed by Indigenous and South Asian patients.

68% of atopic dermatitis patients are chinese, 27% are Aboriginal/ Indigenous, 27% are South Asian, 25% are Other East Asians, 20% are Black, 20% are white, 5% are hispanic, 2% are multiracial and 5% are listed as other.

When asked about the most important factors when recommending an atopic dermatitis treatment, Dermatologists heavily weighted efficacy.

39% said efficacy, 27% safety profile, 16% provincial funding, 9% private insurance coverage and 9% mode of action.

57% agreed that upon approval, abrocitinib should have the same conditions as dupilimab to be used as a systemic therapy. 30% of survey respondents agreed that upon approval, abrocitinib should be limited to second line treatment after dupilumab.

If a patient has facial dematitis, 36% of surveyed dermatologists would prescribe upadacitinib, 16% said tralokinumab, 13% said dupilumab and 33% said other.

When asked what they would do with an uncontrolled patient like Patient A, physicians' responses vary, with nearly half choosing to decrease dose interval.

41% of surveyed dermatologists said they would decrease the interval between doses if their patient was uncontrolled.